Chris Bemben

Mr. Chris Bemben is the Director of Business Development at Lumos Pharma, Inc. (“Lumos”), a clinical stage biotechnology company focused on therapeutics for rare diseases and oncology. Mr. Bemben has a strong background in drug discovery and development as well as experience in strategic licensing, due diligence and financial analysis.

He has led scientific and business offices for small molecule discovery through IND-enabling work for multiple compounds in a variety of disease indications across oncology, neurodegenerative diseases, and viral diseases. He is responsible for developing an evaluation team and negotiating and executing process leading to in-license of LUM-201, a Ph2b rare endocrine product from big pharma.

Currently, he leads large interdisciplinary teams for asset evaluation, due diligence, corporate modeling, and IP review, while also negotiating in- and out-license deals in clinical stage rare disease indications.